These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 38237815)

  • 1. Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients.
    Singh S; Garg A; Tantry US; Bliden K; Gurbel PA; Gulati M
    Curr Probl Cardiol; 2024 Mar; 49(3):102403. PubMed ID: 38237815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
    Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
    Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta-Analysis of Randomized-Controlled Trials.
    Hosseinpour A; Sood A; Kamalpour J; Zandi E; Pakmehr S; Hosseinpour H; Sood A; Agrawal A; Gupta R
    Clin Cardiol; 2024 Jul; 47(7):e24314. PubMed ID: 38953365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of Glucagon-Like Peptide-1 Receptor Agonists to Reduce Adverse Cardiovascular Disease Events in Patients with Type 2 Diabetes Mellitus.
    Grewal S; Zaman N; Borgatta L; Nudy M; Foy AJ; Peterson B
    Am J Cardiol; 2021 Sep; 154():48-53. PubMed ID: 34266665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.
    Qin J; Song L
    BMC Endocr Disord; 2022 May; 22(1):125. PubMed ID: 35546664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study.
    Baviera M; Foresta A; Colacioppo P; Macaluso G; Roncaglioni MC; Tettamanti M; Fortino I; Genovese S; Caruso I; Giorgino F
    Cardiovasc Diabetol; 2022 Aug; 21(1):162. PubMed ID: 35999556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis.
    Stefanou MI; Theodorou A; Malhotra K; Aguiar de Sousa D; Katan M; Palaiodimou L; Katsanos AH; Koutroulou I; Lambadiari V; Lemmens R; Giannopoulos S; Alexandrov AV; Siasos G; Tsivgoulis G
    Eur Stroke J; 2024 Sep; 9(3):530-539. PubMed ID: 38400569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Benefits of GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight: A Meta-analysis of Randomized Controlled Trials.
    de Oliveira Almeida G; Nienkötter TF; Balieiro CCA; Pasqualotto E; Cintra JB; Carvalho HCP; Silva ALS; Kabariti JC; Minucci BS; Bertoli ED; Guida CM
    Am J Cardiovasc Drugs; 2024 Jul; 24(4):509-521. PubMed ID: 38734847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.
    Giugliano D; Longo M; Signoriello S; Maiorino MI; Solerte B; Chiodini P; Esposito K
    Cardiovasc Diabetol; 2022 Mar; 21(1):42. PubMed ID: 35296336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis.
    Diallo A; Carlos-Bolumbu M; Galtier F
    Acta Diabetol; 2023 Dec; 60(12):1651-1662. PubMed ID: 37439858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1 receptor agonists and stroke: A systematic review and meta-analysis of cardiovascular outcome trials.
    Adamou A; Barkas F; Milionis H; Ntaios G
    Int J Stroke; 2024 Oct; 19(8):876-887. PubMed ID: 38676552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials.
    Leite AR; Angélico-Gonçalves A; Vasques-Nóvoa F; Borges-Canha M; Leite-Moreira A; Neves JS; Ferreira JP
    Diabetes Obes Metab; 2022 Aug; 24(8):1676-1680. PubMed ID: 35373878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.
    Mannucci E; Dicembrini I; Nreu B; Monami M
    Diabetes Obes Metab; 2020 Feb; 22(2):203-211. PubMed ID: 31595657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis.
    Malhotra K; Katsanos AH; Lambadiari V; Goyal N; Palaiodimou L; Kosmidou M; Krogias C; Alexandrov AV; Tsivgoulis G
    J Neurol; 2020 Jul; 267(7):2117-2122. PubMed ID: 32246253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis.
    Gargiulo P; Savarese G; D'Amore C; De Martino F; Lund LH; Marsico F; Dellegrottaglie S; Marciano C; Trimarco B; Perrone-Filardi P
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1081-1088. PubMed ID: 29113708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries.
    Wallner M; Biber ME; Stolfo D; Sinagra G; Benson L; Dahlström U; Gudbjörnsdottir S; Cosentino F; Mol PGM; Rosano GMC; Butler J; Metra M; Lund LH; Ferrannini G; Savarese G
    Eur Heart J Cardiovasc Pharmacother; 2024 Jul; 10(4):296-306. PubMed ID: 38632048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.
    Ansari HUH; Qazi SU; Sajid F; Altaf Z; Ghazanfar S; Naveed N; Ashfaq AS; Siddiqui AH; Iqbal H; Qazi S
    Endocr Pract; 2024 Feb; 30(2):160-171. PubMed ID: 38029929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis.
    Stefanou MI; Palaiodimou L; Theodorou A; Safouris A; Fischer U; Kelly PJ; Dawson J; Katan M; Katsanos AH; Lambadiari V; Giannopoulos S; Alexandrov AV; Siasos G; Tsivgoulis G
    Ther Adv Neurol Disord; 2024; 17():17562864241281903. PubMed ID: 39345822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
    Zhang Y; Jiang L; Wang J; Wang T; Chien C; Huang W; Fu X; Xiao Y; Fu Q; Wang S; Zhao J
    Cardiovasc Diabetol; 2022 Nov; 21(1):232. PubMed ID: 36335326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.
    Kang YM; Cho YK; Lee J; Lee SE; Lee WJ; Park JY; Kim YJ; Jung CH; Nauck MA
    Diabetes Metab J; 2019 Aug; 43(4):410-421. PubMed ID: 30604598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.